Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
ACT [NYSE]
Actavis plc
IndexS&P 500 P/E- EPS (ttm)-8.49 Insider Own0.20% Shs Outstand392.77M Perf Week5.24%
Market Cap122.97B Forward P/E14.59 EPS next Y21.46 Insider Trans0.00% Shs Float391.70M Perf Month8.67%
Income-2262.20M PEG- EPS next Q4.40 Inst Own90.90% Short Float1.55% Perf Quarter8.04%
Sales14.64B P/S8.40 EPS this Y-40.80% Inst Trans38.94% Short Ratio2.03 Perf Half Y17.31%
Book/sh229.62 P/B1.36 EPS next Y20.33% ROA-3.20% Target Price347.84 Perf Year48.85%
Cash/sh5.43 P/C57.71 EPS next 5Y16.93% ROE-6.50% 52W Range201.91 - 317.72 Perf YTD21.63%
Dividend- P/FCF63.03 EPS past 5Y-42.20% ROI-2.70% 52W High-1.46% Beta0.35
Dividend %- Quick Ratio1.00 Sales past 5Y36.10% Gross Margin54.10% 52W Low55.06% ATR5.76
Employees21600 Current Ratio1.40 Sales Q/Q59.50% Oper. Margin-10.80% RSI (14)67.83 Volatility1.76% 1.76%
OptionableYes Debt/Eq0.67 EPS Q/Q-436.40% Profit Margin-14.80% Rel Volume1.33 Prev Close306.79
ShortableYes LT Debt/Eq0.64 EarningsMay 11 BMO Payout- Avg Volume2.98M Price313.08
Recom1.60 SMA206.32% SMA505.19% SMA20017.81% Volume3,942,700 Change2.05%
May-15-15Reiterated Susquehanna Positive $325 → $360
May-08-15Initiated Mizuho Buy $358
Apr-15-15Reiterated Barclays Equal Weight $285 → $300
Mar-30-15Reiterated RBC Capital Mkts Top Pick $330 → $361
Mar-03-15Reiterated Deutsche Bank Buy $330 → $336
Feb-20-15Reiterated Argus Buy $310 → $340
Feb-19-15Reiterated RBC Capital Mkts Top Pick $325 → $330
Feb-19-15Reiterated Canaccord Genuity Buy $300 → $352
Jan-21-15Reiterated Deutsche Bank Buy $280 → $330
Jan-13-15Reiterated CRT Capital Buy $270 → $288
Nov-21-14Reiterated Argus Buy $285 → $310
Nov-20-14Reiterated RBC Capital Mkts Top Pick $291 → $323
Nov-18-14Reiterated UBS Buy $278 → $333
Nov-06-14Reiterated RBC Capital Mkts Top Pick $286 → $291
Sep-22-14Downgrade Barclays Overweight → Equal Weight $250 → $250
Aug-06-14Reiterated UBS Buy $237 → $254
Jul-02-14Reiterated CRT Capital Buy $245 → $275
Jun-27-14Initiated Canaccord Genuity Buy $275
May-12-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
May-01-14Reiterated CRT Capital Buy $230 → $245
May-28-15 05:40PM  Is Top-Rated Drug Stock Actavis Ready To Rally Again? at Investor's Business Daily
05:38PM  Actavis' Viberzi Gets FDA Nod for Irritable Bowel Syndrome - Analyst Blog
03:46PM  Amarin's Lawsuit Could Have Huge Benefits For Pharma Industry And Dire Consequences For Consumers at Forbes
02:41PM  Valeant, Actavis Neck And Neck With Bowel Disorder Drugs
02:40PM  Valeant Pharmaceuticals Gets FDA Nod for Xifaxan for IBS-D - Analyst Blog
01:40PM  With A $1.2 Billion Hammer, The FTC Closes Loophole To Prevent Generic Drugs at Forbes
01:14PM  FDA asks dermal filler makers to indicate risk of serious injury Reuters
12:07PM  Actavis, Valeant Up On Bowel-Disease Drug Approvals at Investor's Business Daily
11:20AM  Buy Actavis For Its High Growth, Low Valuation Says Citi at Barrons.com
10:18AM  The top 5 stocks held by billionaires at MarketWatch
May-27-15 07:57PM  FDA Clears Two Irritable Bowel Syndrome Treatments at The Wall Street Journal
05:31PM  Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults PR Newswire
05:02PM  FDA approves Actavis, Valeant drugs for irritable bowel syndrome Reuters
02:54PM  Actavis PLC (ACT), Pfizer Inc. (PFE) Among the Most Popular Healthcare Stocks of Billionaire Investors at Insider Monkey
09:00AM  Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID to Accelerate the Battle Against Antibiotic-resistant Infections PR Newswire
May-26-15 03:12PM  5 most popular health-care stocks among hedge funds at MarketWatch
12:30PM  Actavis to Continue Selling Namenda IR under Court Ruling - Analyst Blog
11:39AM  5 Most Popular Healthcare Stocks Among Hedge Funds at Insider Monkey
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis and Alkermes - Press Releases
08:02AM  5 Drugs That Could Be Summer Blockbusters at Investor's Business Daily
May-25-15 09:35AM  Billionaire Noam Gottesmans Top Stock Picks ~ Actavis plc (ACT), Apple Inc. (AAPL), Cheniere Energy, Inc. (LNG) at Insider Monkey
08:02AM  Considering the Investment Impact of Baby Boomers Retirement
May-22-15 11:54PM  Actavis Must Keep Selling Old Version of Alzheimers Drug Namenda, Court Rules at The Wall Street Journal
04:05PM  Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR PR Newswire
02:30PM  Actavis hard switch
01:55PM  US appeals court upholds delay in Alzheimer's drug swap
01:27PM  Billionaire James Dinans Diversified Portfolio Reveals Bullish Bets on Pepsi, American Airlines & Actavis at Insider Monkey
12:28PM  5 Investments That Show John Paulson Knows How to Play M&A at TheStreet
12:03PM  How Much is Actavis Worth? A Lot More Than It is Now at Barrons.com
10:51AM  Actavis cannot drop old version of Alzheimer's drug - appeals court Reuters
May-21-15 01:00PM  50 stocks that matter most to hedge-fund Masters of the Universe at MarketWatch
09:49AM  5 Stocks the Biggest Hedge Funds Bought Last Quarter at TheStreet
09:34AM  Billionaire Dan Loeb Slightly Shuffles Third Points Top Picks, Selling Off Large Alibaba Group Holding Ltd (BABA) Stake at Insider Monkey
May-20-15 04:05PM  Actavis to Present at Bernstein's Thirty-First Annual Strategic Decisions Conference 2015 PR Newswire
02:50PM  Top 10 stocks of the David Letterman era
02:12PM  Hedge Funds Love These 5 Big Stocks -- but Should You? at TheStreet
11:54AM  Botox Seems To Ease Depression at Forbes
09:50AM  Actavis Plc (ACT), Illumina Inc (LMN) and Cheniere Energy Inc (LNG) Among Billionaire Halvorsens Top Stock picks at Insider Monkey
09:29AM  10 S&P 500 Companies to Have the Most Revenue Growth in 2015 at TheStreet
08:25AM  Do R&D Costs Matter When It Comes To Drug Pricing? at Forbes
07:21AM  Why this pro is doubling down on these 3 stocks
May-19-15 03:16PM  Medtronic PLC (MDT), Actavis plc (ACT): Zweig-DiMenna Partners Top Picks from Healthcare Sector at Insider Monkey
01:36PM  Good year for stock pickers: Pro
12:56PM  Amazon.com, Inc. (AMZN), Citizens Financial Group Inc (CFG), Twitter Inc (TWTR): Hedge Funds Buying Up These Five Stocks at Insider Monkey
12:17PM  Billionaire Lee Cooperman Unveils His Top Picks For The First Quarter at Insider Monkey
10:21AM  The Tax Takeover Craze at The Wall Street Journal
09:34AM  Apple Inc. (AAPL) Dethroned by Actavis plc (ACT) as Hedge Funds Top Stock Pick at Insider Monkey
09:15AM  Pharmacyclics (PCYC), DIRECTV (DTV), Actavis (ACT): Farallon Capital Betting On Merger Arb Plays at Insider Monkey
May-18-15 01:00PM  Smart money cools on Alibaba, other themes from hedge-fund portfolios at MarketWatch
10:10AM  Synergy Rallies 18% Following News of Paulson & Co. Stake
09:35AM  Morgan Stanley's 4 Health Care and Pharma Stocks to Buy for the Long Term at TheStreet
09:01AM  The Symmetric Top Twenty: heres what the best of the best are doing in the market
08:00AM  Actavis Launches NAMZARIC (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease PR Newswire
07:39AM  How to play weak Q2 earnings season: Analysts at CNBC
May-17-15 10:49AM  John Paulson Continues To Bet On Health Care And TV
06:47AM  The Botox initiation of Brent Saunders, Actavis chief executive at Financial Times
May-16-15 07:49PM  John Paulson Buys Actavis, AIG, Valeant, Sells Equinix, Alibaba
01:04PM  ACTAVIS PLC Financials
09:54AM  Bill Ackman's Latest Moves In Health Care & Some Other Positions From Q1
May-15-15 05:51PM  Ackman's Pershing Square Slashes Stake in Combined the Allergan/Actavis at The Wall Street Journal
02:18PM  Tiger Management Likes Chinese Tech Stocks, Cheniere Energy And Actavis
09:57AM  Apple Inc. (AAPL) Leading in Popularity Among Hedge Funds Heading Into Final Filing Day at Insider Monkey
May-14-15 11:58PM  Actavis Has Discussed Settling Federal Probe of Warner Chilcott Sales Tactics at The Wall Street Journal
11:58PM  [$$] Can FDA Reclassify Generic Drugs? at The Wall Street Journal
09:53PM  Actavis says Warner Chilcott unit held talks to settle U.S. probe Reuters
06:26PM  Actavis in Talks About Settling Probe of Warner Chilcott Sales at The Wall Street Journal
May-13-15 10:08AM  Howard Marks' Top 5 New Buys of First Quarter
May-12-15 04:05PM  Actavis to Present at UBS Global Healthcare Conference 2015 PR Newswire
12:54PM  Leerink Is Changing Targets At These 7 Biotechs
11:56AM  Blue Ridge Capital Reduces Position in Actavis
11:55AM  Blue Ridge Capitals Top Positions in 4Q14
10:11AM  Story Stocks from Briefing.com Briefing.com
10:10AM  Stock Market News for May 12, 2015 - Market News
06:00AM  Jim Cramer: Why Doesnt Apple Just Go Ahead and Buy Netflix? at TheStreet
May-11-15 07:24PM  Cramer Remix: I'm making a bold call on China at CNBC
06:36PM  Actavis Earnings Strong, Gives 2015 Guidance
06:11PM  Cramer: CRM? Yelp? Genius mergers, ready to pop at CNBC
06:00PM  Cramer: The power of great acquisitions
02:24PM  Actavis revenue jumps 59 percent after buying Allergen
02:07PM  Actavis (ACT) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
12:37PM  Actavis: You Like My Earnings, You Really, Really Like My Earnings at Barrons.com
11:58AM  Actavis expects Allergan business to drive 2015 growth
11:11AM  Actavis, Caterpillar, Joy jump; Etsy, Noble drop at MarketWatch
11:10AM  Actavis Tops 1Q Earnings by Wide Margin, Provides Outlook - Analyst Blog
10:59AM  Actavis Q1 Beats Estimates, Includes Allergan In 2015 Guidance at Investor's Business Daily
10:33AM  Stocks lower as Street digests jobs; Cisco jumps 1% at CNBC
09:54AM  Actavis Quarterly Earnings Beat Estimates as Sales Rise at Bloomberg
09:52AM  Actavis (ACT) Stock Jumps on Strong First Quarter Earnings at TheStreet
09:05AM  Stock Futures Narrowly Lower; Actavis, AerCap Holdings Jump at Investor's Business Daily
08:30AM  Actavis beats earnings estimates
08:14AM  Actavis (ACT) Beats on Q1 Earnings & Revenues Again - Tale of the Tape
08:12AM  China Cuts Interest Rates Again; Is the Third Time the Charm? at TheStreet
07:50AM  Early movers: DISH, ACT, ROSE, HLT, BID & more at CNBC
07:17AM  10 things you need to know before the opening bell
07:07AM  Q1 2015 Actavis PLC Earnings Release - Before Market Open
06:54AM  Actavis reports 1Q loss
06:45AM  Actavis revenue jumps 60 pct
06:37AM  ACTAVIS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
06:30AM  Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30 PR Newswire
05:58AM  Stocks could rally this week at CNBC
Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician's offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has a collaboration agreements with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.